Blute ML, Leibovich BC, Lohse CM et al (2004) The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int 94(1):33–41. https://doi.org/10.1111/j.1464-410X.2004.04897.x

Article  PubMed  Google Scholar 

Motzer RJ, Jonasch E, Agarwal N et al (2022) Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20(1):71–90. https://doi.org/10.6004/jnccn.2022.0001

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rathmell WK, Rumble RB, Van Veldhuizen PJ et al (2022) Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. J Clin Oncol 40(25):2957–2995. https://doi.org/10.1200/JCO.22.00868

Article  CAS  PubMed  Google Scholar 

Ljungberg B, Albiges L, Abu-Ghanem Y et al (2022) European association of urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol 82(4):399–410. https://doi.org/10.1016/j.eururo.2022.03.006

Article  PubMed  Google Scholar 

Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277–1290. https://doi.org/10.1056/NEJMoa1712126

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116–1127. https://doi.org/10.1056/NEJMoa1816714

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Penkov K, Haanen J et al (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1103–1115. https://doi.org/10.1056/NEJMoa1816047

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choueiri TK, Powles T, Burotto M et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384(9):829–841. https://doi.org/10.1056/NEJMoa2026982

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer R, Alekseev B, Rha SY et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384(14):1289–1300. https://doi.org/10.1056/NEJMoa2035716

Article  CAS  PubMed  Google Scholar 

Singla N, Hutchinson RC, Ghandour RA et al (2020) Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: an analysis of the National cancer database. Urol Oncol 38(6):604.e609-604.e617. https://doi.org/10.1016/j.urolonc.2020.02.029

Article  CAS  Google Scholar 

Yoshida K, Hata K, Iizuka J et al (2022) Immune checkpoint inhibitor combination therapy for renal cell carcinomas with concomitant inferior vena cava thrombi. In Vivo 36(2):1030–1034. https://doi.org/10.21873/invivo.12798

Article  PubMed  PubMed Central  Google Scholar 

Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794–5799. https://doi.org/10.1200/JCO.2008.21.4809

Article  CAS  PubMed  Google Scholar 

Sobin LH, Compton CC (2010) TNM seventh edition: what’s new, what’s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer 116(22):5336–5339. https://doi.org/10.1002/cncr.25537

Article  PubMed  Google Scholar 

Neves RJ, Zincke H (1987) Surgical treatment of renal cancer with vena cava extension. Br J Urol 59(5):390–395. https://doi.org/10.1111/j.1464-410x.1987.tb04832.x

Article  CAS  PubMed  Google Scholar 

Ishihara H, Nemoto Y, Nakamura K et al (2023) Comparison of outcomes between therapeutic combinations based on immune checkpoint inhibitors or tyrosine kinase inhibitor monotherapy for first-line therapy of patients with advanced renal cell carcinoma outside of clinical trials: a real-world retrospective multi-institutional study. Target Oncol 18(2):209–220. https://doi.org/10.1007/s11523-023-00956-8

Article  PubMed  Google Scholar 

Ishiyama Y, Kondo T, Yoshida K et al (2022) “Thrombus-first” or “thrombus-last” approach for surgical management of renal cell carcinoma with inferior vena cava thrombus. Int J Urol 29(6):559–565. https://doi.org/10.1111/iju.14846

Article  PubMed  Google Scholar 

Motoyama D, Ito T, Sugiyama T et al (2022) Robot-assisted radical nephrectomy and inferior vena cava tumor thrombectomy: initial experience in Japan. IJU Case Rep 5(3):145–148. https://doi.org/10.1002/iju5.12419

Article  PubMed  PubMed Central  Google Scholar 

Kondo T, Takagi T, Morita S et al (2015) Early unclamping might reduce the risk of renal artery pseudoaneurysm after robot-assisted laparoscopic partial nephrectomy. Int J Urol 22(12):1096–1102. https://doi.org/10.1111/iju.12902

Article  PubMed  Google Scholar 

Haferkamp A, Bastian PJ, Jakobi H et al (2007) Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. J Urol 177(5):1703–1708. https://doi.org/10.1016/j.juro.2007.01.039

Article  PubMed  Google Scholar 

Klatte T, Pantuck AJ, Riggs SB et al (2007) Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol 178(4):1189–1195. https://doi.org/10.1016/j.juro.2007.05.134

Article  PubMed  Google Scholar 

Cost NG, Delacroix SE, Sleeper JP et al (2011) The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol 59(6):912–918. https://doi.org/10.1016/j.eururo.2011.02.032

Article  CAS  PubMed  Google Scholar 

Bigot P, Fardoun T, Bernhard JC et al (2014) Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful? World J Urol 32(1):109–114. https://doi.org/10.1007/s00345-013-1088-1

Article  CAS  PubMed  Google Scholar 

Ujike T, Uemura M, Kawashima A et al (2016) Clinical and histopathological effects of presurgical treatment with sunitinib for renal cell carcinoma with inferior vena cava tumor thrombus at a single institution. Anticancer Drugs 27(10):1038–1043. https://doi.org/10.1097/CAD.0000000000000422

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fukuda H, Kondo T, Takagi T et al (2017) Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma. Int J Clin Oncol 22(4):767–773. https://doi.org/10.1007/s10147-017-1119-9

Article  CAS  PubMed  Google Scholar 

Okamura Y, Terakawa T, Sakamoto M et al (2019) Presurgical pazopanib improves surgical outcomes for renal cell carcinoma with high-level IVC tumor thrombosis. In Vivo 33(6):2013–2019. https://doi.org/10.21873/invivo.11698

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stewart GD, Welsh SJ, Ursprung S et al (2022) A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). Br J Cancer 127(6):1051–1060. https://doi.org/10.1038/s41416-022-01883-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Labbate C, Hatogai K, Werntz R et al (2019) Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. J Immunother Cancer 7(1):66. https://doi.org/10.1186/s40425-019-0546-8

Article  PubMed  PubMed Central  Google Scholar 

Okada T, Hamamoto S, Etani T et al (2020) Complete response of renal cell carcinoma with an inferior vena cava tumor thrombus and lung metastases after treatment with nivolumab plus ipilimumab. Int Cancer C